United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $541.60 on Thursday. The firm’s 50-day moving average is $493.58 and its 200-day moving average is $471.33. The company has a market cap of $23.74 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 1.92 and a beta of 0.84. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $549.50.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter last year, the company earned $6.19 earnings per share. The firm’s revenue was up 7.4% on a year-over-year basis. Equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. TD Cowen lifted their price objective on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Bank of America restated a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $549.91.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently modified their holdings of the stock. Clearstead Advisors LLC lifted its position in shares of United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares during the period. Independent Advisor Alliance grew its position in United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 27 shares during the period. Bessemer Group Inc. raised its stake in United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 28 shares in the last quarter. Florida Financial Advisors LLC raised its stake in United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 28 shares in the last quarter. Finally, NDVR Inc. lifted its holdings in shares of United Therapeutics by 5.1% during the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 30 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Several brokerages have lifted price targets and reiterated buy/outperform views (examples cited include HC Wainwright, RBC, Cantor Fitzgerald and UBS), supporting upside expectations and helping sentiment. Analyst Coverage Summary
• Positive Sentiment: Wells Fargo published a bullish forecast for UTHR, calling for meaningful price appreciation and adding directional support to the tape. Wells Fargo Research
• Positive Sentiment: Recent quarterly results showed EPS outperformance versus consensus (EPS beat), underpinning the fundamental case even as revenue slightly missed; analysts’ upward revisions follow those results. Quarterly Results Summary
• Neutral Sentiment: Brokerage consensus remains a “Moderate Buy” — constructive but not unanimous; this keeps expectations elevated but measured. Analyst Consensus
• Neutral Sentiment: Institutional ownership is high and several funds reported increasing stakes in recent quarters, which can support liquidity and reduce volatility. Institutional Holdings
• Negative Sentiment: Insider selling: CEO Martine Rothblatt sold 9,500 shares (~$5.0M) and CFO James Edgemond sold 10,000 shares (~$5.27M) in March; large officer sales can pressure sentiment even if company says sales are routine. SEC filings: CEO sale CEO SEC Filing, CFO sale CFO SEC Filing
• Neutral Sentiment: Short-interest reports in recent feeds show data anomalies (zero reported shares / NaN changes) and are not providing a clear short-squeeze or bearish signal at this time. Short Interest Data

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.